Abstracts tagged "Polyarteritis nodosa"

Abstract Number: 1962 • ACR Convergence 2024
Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis
Nouran Eshak¹, Kristina Yancey², Felipe Martinez³, Lester Mertz¹, carolyn mead harvey⁴, Kenneth Warrington⁵, Matthew Koster⁵ and Megan Sullivan¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ, ³Mayo Clinic Arizona, Phoenix, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Rochester, MN
Background/Purpose: Medium vessel vasculitis (MVV), including polyarteritis nodosa (PAN), presents significant diagnostic challenges with patients frequently exhibiting non-specific systemic manifestations. While 18F-fluorodeoxyglucose PET/CT (PET/CT) is…
Abstract Number: 2504 • ACR Convergence 2024
Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Paul Cioni¹, Yann Nguyen², Julien ROHMER³, Henry Dupuy⁴, Xavier Puéchal⁵, Estibaliz Lazaro⁶, Grégory Pugnet⁷, Cécile-Audrey Durel⁸, Edoardo Conticini⁹, François Lifermann¹⁰, Philip Bielefeld¹¹, pierre duffau⁴, Hartmut Mahrhofer¹², Alexis Régent⁵, Loïc Guillevin¹³, ludovic trefond¹⁴, Christian AGARD¹⁵, Alice Bérezné¹⁶, Valentin Lacombe¹⁷, Perrine SMETS¹⁸, Sophie Georgin-lavialle¹⁹, Arsene Mekinian²⁰ and Benjamin Terrier²¹, and the French Vasculitis Study Group and the French Vexas Group, ¹Cochin University Hospital, Paris, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³APHP, Suresnes, France, ⁴Bordeaux University Hospital, Bordeaux, France, ⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁶Bordeaux University Hospital, Pessac, France, ⁷Toulouse Rangueil University Hospital, Toulouse, France, ⁸Edouard Herriot University Hospital, Lyon, France, ⁹University of Siena, Siena, Siena, Italy, ¹⁰Dax Hospital, Dax, France, Dax, France, ¹¹Dijon University Hospital, Dijon, France, ¹²Kirchheim Clinic, Kirchheim unter Teck, Germany, ¹³National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁴Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁵Nantes University Hospital, Nantes, France, ¹⁶Annecy Genevois Hospital, Annecy, France, ¹⁷Angers University Hospital, Angers, France, ¹⁸Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ¹⁹Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²⁰Saint Antoine University Hospital, Paris, France, ²¹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis affecting medium-sized vessels. It is a life-threatening disease without appropriate treatment. In 2024, approximately one quarter…
Abstract Number: 2647 • ACR Convergence 2024
Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients
Aman Sharma¹, Niladri Bhowmick², shankar naidu³, Varun Dhir⁴, Prateek Bhatia³, Vishal Sharma³, sagar Bhattad⁵, Chengappa Kavadichanda⁶, Vikas Gupta⁷, Durga P Misra⁸, Sourabh Malviya⁹, DUDAM RAJKIRAN¹⁰, Banwari Sharma¹¹, John Mathew¹², Sathish Kumar¹³, Rajesh Bhojwani¹⁴, Aadhaar Dhooria¹⁵, Avinash Jain¹⁶, Pankaj Gupta¹⁷, Vikas Agarwal⁸, Rudrarpan Chatterjee¹⁸, Kusum Sharma¹⁹, Manphool Singhal¹⁹, Harjeet Singh¹⁹, Alpana Parmar²⁰, Padmanbha Shenoy²¹, Ritambhra Nada¹⁹, Ranjana Minz¹⁹, Archana Khan²², Sodality Sutnga²², Minu Singh¹⁹, Kaushik Bhojani²³, MAHABALESHWAR MAMADAPUR²⁴, Manesh Manoj²⁵, Puja Srivastava²⁶, Adarsh MB²⁷, Kavita Krishna²⁸, Ramesh Jois²⁹, Vir Singh Negi³⁰, Amita Aggarwal³¹, sanjay jain¹⁹, Raju Khubchandani³², Chip Chambers³³ and Pui Lee³⁴, ¹PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ²Post Graduate Institute of Medical Education and Research , Chandigarh, Chandigarh, Chandigarh, India, ³PGIMER, Chandigarh, India, Chandigarh, India, ⁴PGIMER, CHD, INDIA, CHANDIGARH, India, ⁵2Aster CMI Hospital, Bengaluru, India, Bengaluru, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Fortis Hospital, Ludhiana, India, Ludhiana, ⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁹Medanta superspeciality hospital, Indore, India, ¹⁰Hyderabad Rheumatology Centre, Hyderabad, India, HYDERABAD, Andhra Pradesh, India, ¹¹Niramaya Healthcare, Jaipur, India, Jaipur, India, ¹²Christian Medical college , Vellore , India, Vellore, India, ¹³CMC, Vellore, Vellore, India, ¹⁴Santokba Durlabhji Memorial Hospital, Jaipur, India, Jaipur, India, ¹⁵Mahatma Gandhi Medical College and Hospital Jaipur, Jaipur, Rajasthan, India, ¹⁶Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹⁷PGIMER, Chandigarh, India, Chandigarh, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ¹⁹PGIMER, Chandigarh, Chandigarh, India, ²⁰Rheumatology Clinic, Surat, India, Surat, India, ²¹Center for arthritis and rheumatims excellence ( CARE, Cochin, Kerala, India, ²²SRCC Children’s Hospital, Mumbai, India, Mumbai, India, ²³Fortis Hospital, Mumbai, Mumbai, India, ²⁴JSS MEDICAL COLLEGE AND HOSPITAL,JSSAHER, Mysore, Karnataka, India, ²⁵AKG Memorial Cooperative Hospital Kannur, Nileshwar, Kerala, India, ²⁶STAR Rheumatology Clinics, Ahmedabad, India, Ahmedabad, India, ²⁷Government Medical College, Kozhikode, India, Kozhikode, India, ²⁸Bharati Vidyapeeth Medical College, Pune, Pune, India, ²⁹Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, ³⁰AIIMS, Bilaspur, Puducherry, Puducherry, India, ³¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ³²SRCC Childrens Hospital, Mumbai, India, ³³Vanderbilt University Medical Center & DADA2 Foundation, Franklin, TN, ³⁴Boston Children's Hospital, Newton, MA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare and potentially life threatening monogenic disorder characterized by systemic vasculitis, bone marrow failure, and immunodeficiency.…
Abstract Number: 1626 • ACR Convergence 2023
Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study
Shamma Alzaabi¹, Else Bosman¹, David Cabral², Kimberly Morishita¹ and PedVas Investigators Network³, ¹Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada, ²BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Pediatric Rheumatology, British Columbia Children Hospital, Vancouver, Canada, Vancouver, BC, Canada
Background/Purpose: Childhood polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation that typically affects small and medium-sized arteries. The clinical presentation is variable; it…
Abstract Number: 096 • 2023 Pediatric Rheumatology Symposium
DADA2 – a Case Series from North India
Manjari Agarwal, Jyotsna verma, ratna puri and Sujata Sawhney, Sir Ganga Ram Hospital, New Delhi, India
Background/Purpose: We present a series of children previously diagnosed and managed as Polyarteritis nodosa at our unit. Due to ease of availability of mutation analysis…
Abstract Number: 2232 • ACR Convergence 2022
Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients
Julien ROHMER¹, ludovic trefond², Yann Nguyen³, Christian Agard⁴, Jean Sebastien ALLAIN⁵, Alice Berezne⁶, Pierre Charles⁷, Pascal Cohen⁸, guillaume gondran⁹, Matthieu GROH¹⁰, Tessa HUSCENOT¹¹, carole lacout¹², Estibaliz Lazaro¹³, Jonathan London¹⁴, Francois Maurier¹⁵, Arsene Mekinian¹⁶, Isabelle Nubourgh¹⁷, Rafik MESBAH¹⁸, Xavier Puéchal⁸, Laurent Perard¹⁹, Mathieu Puyade²⁰, Gregory Pugnet²¹, Viviane Queyrel²², Diane Rouzaud²³, Arthur Roux²⁴, Cecile-Audrey DUREL¹⁹, Loïc Guillevin⁸ and Benjamin Terrier⁸, ¹APHP, Suresnes, France, ²Chu clermont ferrand, Clermont-Ferrand, France, ³AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵CHU rennes, Rennes, ⁶CH Annecy, Annecy, France, ⁷Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁹CHU limoges, Limoges, France, ¹⁰Foch Hospital, Suresnes, France, ¹¹APHP, Boulogne, France, ¹²CHU Angers, Angers, France, ¹³Bordeaux Hospital University, Bordeaux, France, ¹⁴Hôpital Croix-Saint-Simon, Paris, France, ¹⁵Hôpitaux privés de Metz, Metz, France, ¹⁶AP-HP, Hopital Saint Antoine, Paris, France, ¹⁷Ch St Pierre, Brussels, Belgium, ¹⁸Boulogne Ch, Boulogne, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Centre Hospitalier Universitaire de Poitiers, Poitiers, France, ²¹CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, ²²CHU NIce, Nice, France, ²³Bichat, Paris, France, ²⁴MGEN, Paris, France
Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
Abstract Number: 1880 • ACR Convergence 2021
Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Young³, Cristina Burroughs⁴ and Peter Merkel⁵, ¹Vanderbilt University Medical Center, Franklin, TN, ²University of California Los Angeles, West Hills, CA, ³Vasculitis Foundation, Kansas City, MO, ⁴Health Informatics Institute, Tampa, FL, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional…
Abstract Number: 1884 • ACR Convergence 2021
Real-life Data for the Use of Anti-TNF Treatment in DADA2
Omer Karadag¹, Gizem Ayan², Ozge Basaran³, Ertugrul Cagri bolek⁴, Levent Kilic², Yelda Bilginer⁵, Mehmet Alikasifoglu⁶ and Seza Ozen⁷, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University Pediatric Rheumatology, Ankara, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁶Hacettepe University, Department of Medical Genetics, Ankara, Turkey, ⁷Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 enzyme (DADA2) is an autosomal recessive autoinflammatory disorder associated with ADA2 mutations. ADA2 works as a growth factor and…
Abstract Number: 1429 • ACR Convergence 2020
An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US
Kathryn Starzyk¹, Kimberly Milberg¹, Ashish Deshpande¹ and Gary Curhan¹, ¹OM1, Inc, Boston, MA
Background/Purpose: The mainstay of treatment for vasculitis has been corticosteroids and other cytotoxic and immunosuppressive medications (e.g., cyclophosphamide, methotrexate) to promptly achieve and maintain remission.…
Abstract Number: 0418 • ACR Convergence 2020
Prevalence of Thyroid Disease Among Patients with Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹David Geffen School of Medicine / University of California, Los Angeles, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous studies have reported higher risk of thyroid disease in patients with giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) compared to age- and…
Abstract Number: 1685 • 2019 ACR/ARP Annual Meeting
Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Due to the rarity of polyarteritis nodosa (PAN), no study has ever investigated inpatient characteristics, healthcare utilization and frequency of comorbidities of patients with…
Abstract Number: 1689 • 2019 ACR/ARP Annual Meeting
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa
Alice Canzian ¹, Omer Karadag ², Anne Contis ³, François Maurier ⁴, Silvia Sartorelli ⁵, Laure Denis ⁶, Sébastien Sanges ⁷, Claire de Moreuil ⁸, Cécile-Audrey Durel ⁹, Stéphane Durupt ¹⁰, Marie Jachiet ¹¹, Diane Rouzaud ¹², Carlo Salvarani ¹³, Franco Schiavon ¹⁴, Lorenzo Dagna ¹⁵, Fabrice Bonnet ¹⁶, David Jayne ¹⁷, Loic Guillevin ¹⁸ and Benjamin Terrier¹, ¹Cochin Hospital, Paris, France, ²Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ³Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁵Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁶Clermont-Ferrand Hospital, Clermont-Ferrand, France, ⁷CHRU Lille, Lille, France, ⁸CHU Brest, Brest, France, ⁹Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Lyon Hospital, Lyon, France, ¹¹Saint Louis Hospital, Paris, France, ¹²Bichat Hospital, Paris, France, ¹³Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁴Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ¹⁶CHU Bordeaux, Bordeaux, France, ¹⁷Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis of medium- and small-sized arteries, not associated with antineutrophil cytoplasmic antibodies (ANCA). Conventional treatments include…
Abstract Number: 2742 • 2017 ACR/ARHP Annual Meeting
A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts
Omer Karadag^1,2, Abdulsamet Erden², Yelda Bilginer², Seerapani Gopaluni¹, Alper Sari², Berkan Armagan², Ihsan Ertenli², Seza Ozen² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Polyarteritis Nodosa (PAN) is a rare subgroup of the primary vasculitides. There are only two published cohorts describing demographic and clinical features of the disease.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].